Huabo goes pivotal with bispecific VEGF trap
The company takes a PD-L1 x VEGF asset into phase 3.
BridgeBio Oncology shows early promise
The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.
Instil’s bispecific dream is over
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
NACLC 2025 – BioNTech gets a gotistobart boost
The first stage of Preserve-003 shows a survival benefit in post-PD-(L)1 lung cancer – with caveats.
BioNTech’s big gotistobart day approaches
Readout of the Preserve-003 trial in post-PD-(L)1 NSCLC is due in December.
Immatics’ PRAME T-cell engager improves
The response rate jumps to 30% with higher doses of IMA402.
